Beijing博奥晶典生物技术有限公司 is a leading domestic provider of gene testing and biochip-based diagnostics with R&D, production, sales and a nationwide third‑party independent medical laboratory service. The company supplies technology and solutions to life sciences research, medical testing, new drug R&D, health management, forensic testing, agriculture/food safety and related fields. It claims the world’s largest original biochip technology platform, has drafted national standards, and holds more than 300 granted patents with a patent conversion rate near 50%. After completing a Pre-IPO financing of over ¥800 million, the company plans to accelerate new product R&D and expand its chip production lines. Management also intends to strengthen sales, marketing and overseas expansion. In addition, the company will initiate share‑reform work and prepare a科创板 (SSE STAR Market) IPO filing.

Total raised

$113M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2020